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Abstract: The application of nanotechnology in medicine is gaining popularity due to its ability to
increase the bioavailability and biosorption of numerous drugs. Chrysin, a flavone constituent of
Orocylumineicum vent is well‐reported for its biological properties. However, its therapeutic
potential has not been fully exploited due to its poor solubility and bioavailability. In the present
study, chrysin was encapsulated into chitosan nanoparticles using TPP as a linker. The
nanoparticles were characterized and investigated for their anti‐biofilm activity against
Staphylococcus aureus. At sub‐Minimum Inhibitory Concentration, the nanoparticles exhibited
enhanced anti‐biofilm efficacy against S. aureus as compared to its bulk counterparts, chrysin and
chitosan. The decrease in the cell surface hydrophobicity and exopolysaccharide production
indicated the inhibitory effect of the nanoparticles on the initial stages of biofilm development. The
growth curve analysis revealed that at a sub‐MIC, the nanoparticles did not exert a bactericidal
effect against S. aureus. The findings indicated the anti‐biofilm activity of the chrysin‐loaded
chitosan nanoparticles and their potential application in combating infections associated with S.
aureus.
Keywords: biofilm; chitosan; chrysin; nanoparticles; Staphylococcus aureus

1. Introduction
Biofilms—aggregations of densely packed microbial cells embedded inside exopolysaccharide
(EPS) matrix—are a major challenge in public health management. The EPS matrix provides a
protective barrier to the biofilm, making them recalcitrant to antimicrobial agents and host defenses
[1]. Staphylococcus aureus is thought to be one of the major causes of nosocomial infections, globally.
While the planktonic counterpart is limited to bacteremia and skin abscesses, more chronic infections
such as cystic fibrosis, osteomyelitis, and endocarditis are associated with its biofilm mode of growth
[2,3]. To eradicate this problem, many strategies were proposed, including (i) the inhibition of
primary bacterial adhesion or attachment to the living or non‐living surfaces, (ii) the disruption of
biofilm architecture during maturation processes, and (iii) the inhibition of cell to cell
communication—i.e., quorum sensing [4,5]. Chrysin (5, 7‐dihydroxyflavone), a flavone constituent
of the Orocylumineicum vent has already been documented for its anticancer, antioxidant and
antibacterial properties [6,7]. In spite of its many biological activities, its low water solubility, poor

Pathogens 2020, 9, 115

2 of 11

biosorption in the intestinal lumen, low bioavailability and rapid metabolism in the body limits its
therapeutic applications [8]. In this regard, a reduction in particle size may serve as a potential means
for enhancing the solubility and dissolution of chrysin [9].
Nanocarriers have the ability to inhibit bacterial growth and biofilm formation, and are
increasingly being used as an attractive tool to combat chronic infections [10]. They aid in increasing
the efficacy of the drug by acting as a protective barrier against enzymatic hydrolysis, increase the
biosorption efficacy of the drug in the intestinal lumen, increase solubility and also cause sustainable
release [11,12]. In recent years, chitosan is widely being used as a nano‐carrier due to its non‐toxicity,
biocompatibility, immunostimulating and mucoadhesive properties [13]. Chitosan is a cationic
heteropolysaccharide composed of the β‐(1,4) linked repeating unit of glucosamine (GlcN) and N‐
acetylglucosamine (GlcNAc), extracted by the partial alkaline N‐deacetylation of chitin found in the
exoskeleton of crustaceans [14,15]. The antimicrobial and anti‐biofilm potential of chitosan and its
nano‐derivatives were reported against various microorganisms such as Listeria monocytogenes,
Bacillus cereus, Enterococcus faecalis, etc. [1,16]. Chrysin‐encapsulated chitosan nanoparticles (CCNPs),
synthesized using the ionic gelation method, were characterized and evaluated for their anti‐biofilm
activity against S. aureus.
2. Materials and Methods
2.1. Materials
Chitosan (75–85% deacetylated), sodium tripolyphosphate (TPP) and Chrysin were procured
from Sigma‐Aldrich. The test stain, S. aureus (MCC 2408) was purchased from Microbial Culture
Collection (MCC), Pune, India.
2.2. Synthesis of Chrysin‐Loaded Chitosan Nanoparticles
Medium molecular weight chitosan (0.2%, w/v) was mixed with an aqueous solution of acetic
acid (0.1%, v/v) and incubated over‐night at 60 °C with continuous agitation. A stock of 5 mg/mL of
chrysin dissolved in DMSO was used to prepare the nanoparticle formulation. An aliquot of chrysin
prepared in DMSO was added to the chitosan solution (pH 4.8). Subsequently, 40 mL of TPP solution
(0.2%, w/v) was dispensed dropwise into the chitosan–chrysin solution and kept under continuous
agitation at 1000 × g for 30 min. The ratio of the chitosan‐TPP was maintained at 5:1 [13] with the final
chrysin concentration of 50 μg/mL. The nanoparticles formed were concentrated by centrifuging the
suspension for 20 min at 12,000 × g, washed with MilliQ water to remove the unbound chrysin and
dried at room temperature for further studies [17].
2.3. Physical Characterization of Nanoparticles
The nanoparticles (NPs) were subjected to dynamic light scattering (DLS) to determine the mean
hydrodynamic diameter (MHD) and polydispersity index (PDI). The FTIR spectrum was recorded in
the range of 4000–500 cm−1. A transmission electron microscope (TEM) was used to determine the
morphology and size of the CCNPs [18].
2.4. Determination of the Loading Efficiency and Drug Release of Chrysin‐Loaded Chitosan NPs
The amount of chrysin loaded in the nanoparticles was determined using a UV‐Vis
spectrophotometer. After the collection of NPs from the reaction mixture, the absorbance of the
supernatant was recorded at 348 nm and the concentration of unbound chrysin was estimated based
on the standard curve of chrysin [13,19]. The CCNPs were dislodged in a medium constituting PBS
and DMSO (co‐solvent, 1%, v/v) and incubated with gentle agitation (100 × g) at 37 °C. Two milliliters
of the sample was retrieved at regular intervals, centrifuged at 10,000 × g and the absorbance of the
supernatant was recorded at 348 nm. The cumulative chrysin released in the medium was determined
at the every 2 h interval, with reference to the standard curve of chrysin [20]. Chrysin release (%) =
(Chrysin released in the supernatant / loaded chrysin concentration) × 100.
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2.5. Determination Sub‐Minimum Inhibitory Concentration (Sub‐MIC) of Chrysin‐Loaded Chitosan NPs
The minimum inhibitory concentration (MIC) of CCNPs was determined using macro‐broth
dilution assay (Clinical and Laboratory Standards Institute Guidelines, 2006). Two‐fold dilutions of
the NPs were prepared in Muller‐Hinton broth to achieve a final concentration ranging from 8 μg/mL
to 1024 μg/mL. An overnight culture of S. aureus (100 μL) was added in each NPs suspension and
incubated at 37 °C for 24 h. The test tubes were observed for visible signs of growth and the
spectrophotometric readings were recorded at 600 nm [12].
2.6. In Vitro Anti‐Biofilm Assays of Chrysin‐Loaded Chitosan NPs
The effect of sub‐MIC of CCNPs of the on the biofilm formation of S. aureus was evaluated
relative to chitosan NPs (CNPs) and Chrysin.
2.6.1. Microtiter Plate (MTP) Assay for Biofilm Disruption and Inhibition.
MTP assay for biofilm disruption and inhibition was performed according to Mu et al. [1]. An
over‐night culture of S. aureus (100 μL) was transferred into the wells of 96‐well flat‐bottomed
polystyrene plates. After incubation at 37 °C for 24 h, the wells were washed with 100 μL of 0.9%
(w/v) NaCl to remove the unadhered cells. The biofilm formed was further incubated after adding 90
μL tryptone soy broth (TSB) supplemented with the sub‐MIC concentration of CCNPs for another 24
h. The biofilm attached at the bottom of each well was fixed with 100 μL of absolute methanol for 15
min and subsequently treated with 100 μL of crystal violet (0.2% w/v). Control samples were
maintained with S. aureus culture alone. Cultures of S. aureus treated with DMSO serve as a control.
The dye attached to the biofilm was further solubilized in 150 μL of glacial acetic acid and the optical
density was recorded at 595 nm. S. aureus culture (90 μL) grown in TSB was seeded into individual
wells of microtiter plates in the presence of sub‐MIC of CCNPs and incubated at 37 °C for 24 h. The
planktonic cells were discarded and the MTP was stained with crystal violet (0.2% w/v). The
inhibition of biofilm formation was determined by solubilizing the CV attached to the biofilm and
measuring the optical density at 595 nm. Biofilm inhibition/disruption was quantified using the
following formula:
% Biofilm inhibition/disruption= ([OD595 of control − OD595 of test] = OD595 of control) * 100
2.6.2. Microscopic Examination of Biofilm
Reduction in the biofilms of S. aureus was observed using confocal laser scanning microscopy
(CLSM). S. aureus biofilms was allowed to grow on glass coverslips (18 × 18 mm) placed in 12 well
polystyrene plates containing TSB supplemented with CCNPs (sub‐MIC) and incubated overnight at
37 °C. The glass coverslip was washed with sterile distilled water, stained and processed accordingly
[21]. The biofilm formed was fixed using methanol and treated with crystal violet (0.2% w/v). The
coverslip was subsequently washed, air dried and observed using a light microscope (40×). The
biofilm formed on the coverslip was washed 0.01 M phosphate buffer saline (PBS), stained using
acridine orange (0.2% w/v) for 1 min and observed using Confocal laser microscope at 20×. The 3D
image was recorded and Z stacks were prepared to determine the effect of the CCNPs on the
thickness of the biofilm [22].
2.6.3. Exopolysaccharide (EPS) Quantification and Microbial Adhesion to Hydrocarbon
(MATH) Assay
Production of EPS by S. aureus was quantified in presence and absence of CCNPs by total
carbohydrate quantification method. S. aureus was grown in presence and absences of CCNPs were
harvested by centrifugation (10,000 × g for 2 min). The cell pellet was washed and suspended in 200
µL of sterile PBS to which an equal volume of 5% (v/v) phenol and 5× volume of concentrated sulfuric
acid containing 0.2% (w/v) hydrazine sulphate was added. The tubes were incubated in dark for 1 h
followed by centrifugation at 10,000 × g for 10 min. The supernatant was aspirated and the optical
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density was measured at 490 nm [21]. A reduction in EPS production was quantified using the
following formula:
% EPS quantification ൌ ሺሾOD490 of control െ OD490 of testሿ ൊ OD490 of controlሻ ൈ 100
The effect of CCNPs on the cell surface hydrophobicity of S. aureus was evaluated using MATH
assay. The optical density of the treated CCNPs and the untreated cell suspension was recorded at
600 nm, after 24 h of incubation. The bacterial suspension was mixed with toluene (1 mL) and
vortexed for 2 min. The optical density of the aqueous phase was measured at 600 nm. In both the
assays, control samples were maintained with S. aureus culture only. Cultures of S. aureus treated
with DMSO served as a negative control [21]. The percentage of inhibition in hydrophobicity is
measured as follows;
Hydrobhobicity ሺ%ሻ ൌ 1 െ

OD600 after vortexing
ൈ 100
OD600 before vortexing

2.6.4. Growth Curve Analysis
An overnight culture of S. aureus was diluted with LB medium until the optical density of the
cell suspension reaches 0.05 at 600 nm. The suspension was then supplemented with chrysin and NPs
separately and incubated overnight at 37 °C at 100 × g. The cell suspension (1 mL) was withdrawn
and the optical density was measured at 600 nm, at every 2 h interval [23].
2.7. Statistical Analysis
All the assays were repeated thrice, and the data are presented as mean ± standard error.
Significance among treatments were investigated using one‐way ANOVA and represented with a
statistical significance of P ≤ 0.05. Significance in treatments of chrysin, chitosan and CCNPs are
represented with asterisk sign. Non‐significant groups are represented by NS.
3. Results
3.1. Synthesis and Characterization of Chrysin‐Loaded Chitosan NPs
The CCNPs were synthesized using the ionotropic gelation method, using TPP molecules as a
linker. The ratio of chitosan and TPP used is one of the factors that influence the aggregation of
nanoparticles. Chitosan/TPP in the ratio of 5:1 was found to be the best formulation for the synthesis
of CCNPs. The mean hydrodynamic diameter of the synthesized CNPs and CCNPs were found to be
~299 nm and ~355 nm, respectively. CNP and CCNP nanoparticles showed an intermediate
polydisperisty index of 0.434 and 0.487, respectively (Figure 1a; Figure 1b). However, the CCNPs
were found to be spherical with sizes ranging from 130–341 nm as indicated by the TEM micrograph
(Figure 1c). On comparing the functional groups present in the CCNPs with their bulk counterparts,
chitosan showed characteristic peaks at 3418 and 3238 cm−1, which indicated the O‐H stretching and
N–H stretching vibration, the characteristic peak at 2908 cm−1 depicted the C–H stretch, 2342 cm−1 (C–
N band stretching), 1610 cm−1 (amide II band), 1024 and 1051 cm−1 indicated that the CH2 group and
C–O stretch from glucosamine residue was observed. Chrysin showed characteristic bands at 2625
cm−1, 2343 cm−1 indicating O–H stretching vibration and intramolecular H‐bond (Figure 1d). The
characteristic peaks of both chitosan (at 2342 cm−1, 1051 cm−1) and chrysin (at 2625 cm−1 and 2343 cm−1)
were observed in the CCNPs. A slight band shift was also observed at 3347 and 3200 cm−1 to the lower
wave‐number that indicated the presence of hydrogen bonding between O‐H group of chrysin and
O‐H or ‐NH2 group of chitosan [24]. The other peaks observed in the loaded nanoparticles were the
P–O bending peak at 890 cm−1 and at 2625 cm−1, which was broader compared to pure chrysin,
indicating an increase in hydrogen bond interactions [13].
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Figure 1. Characterization of NPs: Size distribution of a) chitosan nanoparticles (CNPs) and b)
chrysin‐encapsulated chitosan nanoparticles (CCNPs); c) TEM micrograph showing polydispersed
CCNPs with size range of 130–341 nm; d) FTIR spectra of chitosan (red), TPP (blue), chrysin (grey)
and CCNPs (green).

3.2. Loading Efficiency and Release Kinetics of Chrysin‐Loaded Chitosan NPs
The amount of chrysin loaded onto the CCNPs was found to be 80.86 ± 0.30%. The in vitro drug
release profile of chrysin from the CCNPs was determined in a release medium constituting PBS and
DMSO, at 37 °C. The pH of the media was set at 7.4, as the ionic strength of the media plays a vital
part in the stability and drug release. The cumulative chrysin release as a function of time is depicted
in Figure 2a. The drug release kinetics of the loaded NPs initially showed a burst release which was
followed by a steady and sustainable release from the 8th h. The first burst release was observed in
the first two hours with 36.33 ± 1.58% of chrysin release. The second burst was observed after the
sixth hour with 80.11% ± 0.84% drug release. The graph takes the form of a plateau starting from the
10th hour to 24th hour. It was also revealed that about a total of 90.5% ± 0.50% of the chrysin was
released from the NPs within 10 h.
3.3. Minimum Inhibitory Concentration (MIC) and Sub‐MIC of Chrysin‐Loaded Chitosan NPs
The MIC value of the CCNPs was determined to be 1024 μg/mL for S. aureus. At 768 μg/mL, the
NPs that did not exert any effect on the growth of the test bacteria. Hence, 768 μg/mL was selected
as a sub‐MIC concentration and used in all the subsequent anti‐biofilm assays.
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3.4. In Vitro Anti‐Biofilm Activity of Chrysin‐Loaded Chitosan NPs
3.4.1. Crystal Violet Staining Assay for Biofilm Formation and Disruption
The CCNPs showed a reduction in biofilm formation as compared to its bulk counterparts. The
biofilms were inhibited to 50.48 ± 2.42% and 54.1 ± 0.56 % on treatment with CNPs and chrysin,
respectively (Figure 2b). However, the CCNPs inhibited the biofilm formation to 66.59 ± 3.09%. The
treatment of the preformed biofilm with CCNPs also resulted in a reduction in the biofilm mass of
43.50 ± 1.29%, whereas a decrease in biofilm of 14.92 ± 2.17% and 20.94 ± 3.73% was observed in the
presence of CNPs and chrysin, respectively (Figure 2c).

Figure 2. Drug release kinetics and Anti‐biofilm assay: a) In vitro release profile of chrysin from
CCNPs at 37 °C and pH 7.4, the data are presented as mean ± SD; Graph showing biofilm b) inhibition
and c) disruption on treatment with DMSO, CNPs, chrysin and CCNPs.

3.4.2. Microscopic Examination of Biofilm
Light microscopy and CLSM were used to observe the change in the biofilm architecture of S.
aureus in presence and absence of CCNPs. The influence of CCNPs on the thickness of biofilm, overall
structure and biofilm density was evident in the micrographs. However, a dense biofilm was visible
in the light microscope images of the untreated samples (Figure 3). A thick biofilm of 80 μm was
observed in the control while the thickness was reduced to 20 μm on treatment with chrysin.
However, a higher reduction in the thickness of the biofilm matrix to 16 μm was achieved in the
presence of CCNPs (Figure 3).

Pathogens 2020, 9, 115

7 of 11

Figure 3. Microscopic examination of biofilm: Light microscopy images of S. aureus biofilm (a)
untreated, treated with (b) CNPs, (c) chrysin and (d) CCNPs, showing dispersion in biofilm
formation. CLSM ‐2D images (e–h) and 3D images (i–l) showing bacterial biofilm of untreated, treated
with CNPs, chrysin and CCNPs respectively.

3.4.3. Exopolysaccharide (EPS) Quantification and Microbial Adhesion to Hydrocarbon
(MATH) Assay
The CCNPs showed better reduction in the synthesis of EPS compared to its bulk counterparts.
On treatment with CCNPs, a reduction in EPS production of 38.03 ± 5.41% was observed (Figure 4a).
Chrysin and CNPs were also able to restrict the production of EPS by 33.37 ± 4.84% and 26.54 ± 3.20%,
respectively. Cell surface hydrophobicity (CSH) is another important factor in biofilm formation as it
aids in the adherence of the cell to the substratum. The CCNPs reduced the CSH in S. aureus by 84.66
± 2.84% as compared to its bulk counter parts (Figure 4b). CNPs and Chrysin showed approximately
61.28 ± 5.78% and 72.46 ± 4.21% decreases in cell surface hydrophobicity, respectively.

Figure 4. a) Exopolysaccharide quantification and b) Microbial adhesion to hydrocarbon assay: Effect
of CNPs, chrysin, and CCNPs on the EPS production and cell surface hydrophobicity of S. aureus.

Pathogens 2020, 9, 115

8 of 11

3.4.4. Growth Curve Analysis
The growth pattern of the test organism when cultivated in the presence and absence of the
CCNPs and CNPs is presented in Figure 5 Though the cells exhibited retardation in growth on
exposure to a sub‐MIC of the NPs and Chrysin, there was no significant decrease in the cell density.
Hence, it can be inferred that the CCNPs arrested the biofilm development in S. aureus, indicating the
potential application of CCNPs in the management of S. aureus‐related infections.

Untreated
CNPs
Chrysin
CCNPs
DMSO

3.0

O.D at 600nm

2.5

2.0

1.5

1.0

0.5

0.0
0

4

8

12

16

20

24

Time (hr)

Figure 5. Growth curve analysis Growth curve of S. aureus incubated with chrysin, CNPs and CCNPs.

4. Discussion
The formation of biofilm is one of the major obstacles in the modern antibacterial therapy. The
biofilm‐forming ability of bacteria provides the pathogen with advantages by blocking the entry of
antimicrobial agents, thus causing hindrance in the clearance of these pathogens by the host immune
system. Drug nanonization—i.e., a reduction in the particle size of drugs to nano‐size—enhances the
intracellular uptake of nanoparticles thus, providing a way to overcome the problems associated with
insoluble drugs. Moreover, an increase in the surface area of poorly soluble drugs also leads to a more
pronounced increase in the therapeutic index by maximizing the action with lesser dose [25]. In the
present study, the anti‐biofilm activity of CCNPs was demonstrated against biofilm forming
bacterium, S. aureus MCC 2408. Chrysin was encapsulated to chitosan using the ionotropic gelation
method. The NPs were formed due to the electrostatic interaction between amine group of chitosan
and polyphosphate ions of TPP [19]. The hydrodynamic size influences various properties such as
loading efficiency, drug release kinetics and the stability of the NPs. Though smaller nanoparticles
due to high surface area show greater encapsulation efficiency, however, it also tends to aggregate
easily on storage [19]. Particles of a low polydispersity index (PDI) are homogenous in nature and
provide maximum stability. High polydispersity index (PDI) indicates the heterogeneity of the
nanoparticles in the mixture. The synthesized spherical nanoparticles showed intermediate
polydispersity that aids in the stability of the CCNPs. Ilk et al. [19] reported the synthesis of
kaempferol loaded chitosan/TPP nanoparticles with an average particle size of 192.27 nm. The FTIR
spectra of CCNPs indicated the presence of a similar functional group as that of its bulk counterpart
indicating the successful encapsulation of chrysin with chitosan and the formation of chrysin‐loaded
chitosan NPs.
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The biological efficacy of a drug and its potential use in drug delivery is directly influenced by
the loading efficiency and controlled release. The CCNPs demonstrated a high encapsulation
efficiency with a sustainable release. The CCNPs showed a higher loading efficiency compared to the
previously synthesized nanocomposites such as the BSA‐loaded chitosan‐TPP nanoparticle with a
loading efficacy of 60% [13] and PEG‐chrysin conjugates with a loading efficacy of 55.6% [26]. The
high encapsulation efficiency of CCNPs may be attributed to the presence of hydrogen bond between
the ‐OH group of chrysin and the ‐NH2 group of chitosan that help in better entrapment of chrysin
into the CNPs. From these release kinetics, it can be interpreted that chrysin was not covalently
bonded to the nanoparticle and was thus easily released when dislodged in the medium. A similar
result was observed in kaempferol‐loaded chitosan nanoparticles, where more than 85% of the drug
release was attained within 4 h, and no significant quantity of the drug was released thereafter [19].
Biofilm formation by S. aureus is associated with many nosocomial as well as chronic diseases
associated with medical devices and surgical implants. It also leads to the emergence of the multi‐
drug resistant (MDR) strains viz. Methicillin‐resistant S. aureus (MRSA) and Vancomycin‐resistant S.
aureus (VRSA) [3]. It was found that both CNPs and chrysin exhibited significant anti‐biofilm activity
relative to the untreated control. However, the anti‐biofilm efficacy was comparatively enhanced
when chrysin was encapsulated with chitosan. The ability to attach and establish biofilm on inert
surfaces contributes to making S. aureus a major pathogen of chronic infections [10]. The data also
suggested that the CCNPs showed better biofilm inhibition ability than disruption of preformed
biofilm. Shi et al. [10] suggested that chitosan‐coated iron oxide nanoparticles have the potential to
effectively prevent bacterial colonization and control the biofilm formation by 53% in S. aureus. The
anti‐biofilm efficacy of the NPs was also validated by light and CLSM micrographs which showed a
reduction in thickness and density of the biofilm matrix in presence of CCNPs.
The EPS matrix plays an indispensable role in the initial cell attachment, the formation of biofilm
architecture and in providing mechanical stability of the biofilm. The EPS produced by the biofilm‐
forming bacteria prevents the access of antimicrobial agents and antibiotics to the bacterial cell [18].
The CCNPs caused a considerable decrease in the EPS production and cell surface hydrophobicity in
S. aureus which resulted in the decrease in bacteria accumulation and attachment to the substratum.
Hence, it can be inferred that CCNPs have a profound effect on the early stages in biofilm formation,
specifically in the adherence and colonization as compared to its bulk counterparts, chrysin and
chitosan.
From the growth curve analysis, it can be interpreted that at the sub‐MIC level, the CCNPs
exerted less bactericidal effect and selective pressure against S. aureus. However, it had a profound
effect on the S. aureus in the biofilm mode of growth. Chrysin and chitosan are found to be nontoxic
in recommended concentrations. It was reported that the recommended daily concentration of this
flavone is 0.5 to 3 g [27]. Likewise, chitosan nanoparticles are nontoxic at low concentrations and
found to be toxic only at higher concentrations [28]. The nontoxic nature of these components may
enable the application of CCNPs for biomedical applications. As these the outcome of the study
suggested that the nanoformulation of chrysin exhibits enhanced synergistic anti‐biofilm activity
against S. aureus when compared to its bulk counterparts—chrysin and chitosan taken separately.
Hence, CCNPs may be considered as a potential therapeutic agent for controlling biofilm formation
in S. aureus. The nanocomposites may be further exploited towards the development of anti‐biofilm
coatings.
5. Conclusions
This study displayed an enhanced antibiofilm activity of chrysin against S. aureus when loaded
on to chitosan‐TPP nanoparticles, with a profound loading capacity. Chrysin‐loaded chitosan
nanoparticles were characterized to confirm the effective loading of the flavone on chitosan
nanoparticles. Anti‐biofilm activities of CCNPs were determined through biofilm inhibition, biofilm
disruption, EPS reduction and hydrophobicity reduction assays. CCNPs synthesized could be used
as a potential therapeutic agent for controlling biofilm formation in S. aureus in the future. The
nanocomposites may be further exploited towards the development of anti‐biofilm coatings.
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